Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02105636 · ClinicalTrials.gov registry record · Phase 3
Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141)
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 361
- Enrollment target
NCT02105636 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 361 participants.
The verdict
NCT02105636, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 361 participants
- Enrollment target
Study Summary
The purpose of this study is to find out whether Nivolumab will significantly improve overall survival as compared to therapy of investigator's choice in patients with recurrent or metastatic head and neck carcinoma.
Interventions
- DRUG Docetaxel
- DRUG Nivolumab
- DRUG Cetuximab
- DRUG Methotrexate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 361 participants |
| Start Date | 2014-05-29 |
| Est. Completion | 2021-09-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02105636
The ClinicalTrials.gov registry entry for NCT02105636 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 361 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Docetaxel is the first listed.
NCT02105636 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02105636 about?
NCT02105636 is a clinical study titled "Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141)". The purpose of this study is to find out whether Nivolumab will significantly improve overall survival as compared to therapy of investigator's choice in patients with recurrent or metastatic head and neck carcinoma.
What is the current status of trial NCT02105636?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 361 participants. The study started on 2014-05-29. Estimated completion is 2021-09-10.
What interventions are being tested in trial NCT02105636?
The interventions under investigation include: Docetaxel (DRUG), Nivolumab (DRUG), Cetuximab (DRUG), Methotrexate (DRUG).
Who is sponsoring clinical trial NCT02105636?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.